Think: clients who cant tolerate aggressive actives but still want anti-ageing progress
Youre at risk of vitamin B12 deficiency
Are there medication interactions or health risks
The Category 2 Ban and the 2026 Reclassification In 2023, the FDA pulled 19 of the most popular peptides BPC-157, TB-500, CJC-1295, among others off the compounding-permitted list and placed them on the restricted Category 2 list, citing safety concerns, impurity issues, and a lack of clinical data
Therapies such as Epithalon, SS-31, GHK-Cu, and NAD+ focus on improving cellular resilience and long-term physiological function
This product is intended for in vitro laboratory research use only